Colleen Delaney, MD, MSc
Deverra Therapeutics
Ketty Gendzekhadze, MSc, PhD, F(ACHI)
City of Hope
Abeer Madbouly, PhD
NMDP
Melody Zhang, MD, A(ACHI)
Stanford University
As the field of cellular therapies evolves, allogeneic therapies are quickly growing and becoming very attractive due to the plethora of available cell sources and the flexibility of building off-the-shelf cell banks. However, histocompatibility between the cell donors and therapy recipients plays an important factor. In particular, the role of HLA matching is unclear in impacting the success of multiple cellular therapies, when to account for it, when to avoid and when to take particular considerations. This session will touch on some recent advances in allogeneic cellular therapies and discuss some important histocompatibility issues cellular therapy developers and testing labs are facing through the experiences of some esteemed experts in the field.
Session developed by Ketty Gendzekhadze, Abeer Madbouly and Jerry Morris, program planning committee.